GSK plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
James Ford |
||||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GSK plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
||||
|
b) |
Nature of the transaction |
The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022 |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
|
e) |
Date of the transaction |
2025-11-28 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
David Redfern |
||||
|
b) |
Position/status |
President, Corporate Development |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GSK plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
||||
|
b) |
Nature of the transaction |
The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022 |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
|
e) |
Date of the transaction |
2025-11-28 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Victoria Whyte |
||||
|
b) |
Position/status |
SVP & Company Secretary |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GSK plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
||||
|
b) |
Nature of the transaction |
The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022 |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
|
e) |
Date of the transaction |
2025-11-28 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG